

January 25, 2006

Pfizer files lawsuit in England regarding licence for Amlodin

Dainippon Sumitomo Pharma Co., Ltd. (DSP) and its parent company Sumitomo Chemical Company (Sumitomo Chemical) have recently been served with a claim for the lawsuit that Pfizer (Pfizer Limited and Pfizer Corp. collectively) has filed with an English court calling for cessation of the manufacture and sale of Amlodin (Generic name: Amlodipine Besilate, a therapeutic drug for hypertension and angina pectoris) and return to Pfizer of all medical data and other information regarding Amlodin, for which Pfizer is the licensor.

Pfizer's lawsuit filed with the English court is substantively the same as its suit already filed in Japan, which claims that the Amlodin license agreement has been terminated as the licensee Sumitomo Pharmaceuticals no longer exists as a result of its merger with Dainippon Pharmaceutical to form DSP.

Sumitomo Chemical and DSP firmly believe that the English court has no jurisdiction in this matter. Even if the court determines that it has jurisdiction, however, Sumitomo Chemical and DSP are confident that the legitimacy of their position that the license agreement remains in effect will be fully affirmed by the English court and that DSP will be able to continue undertaking the Amlodin business with no adverse impact to its earnings.